Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ALDX 
Aldeyra The (ALDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: ALDX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.67
1 Year Target Price $8.67
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.78% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 259.35M USD | Price to earnings Ratio - | 1Y Target Price 8.67 |
Price to earnings Ratio - | 1Y Target Price 8.67 | ||
Volume (30-day avg) 7 | Beta 0.68 | 52 Weeks Range 1.14 - 7.20 | Updated Date 07/9/2025 |
52 Weeks Range 1.14 - 7.20 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.6% | Return on Equity (TTM) -65.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 184856459 | Price to Sales(TTM) - |
Enterprise Value 184856459 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.5 | Shares Outstanding 59895600 | Shares Floating 47667904 |
Shares Outstanding 59895600 | Shares Floating 47667904 | ||
Percent Insiders 3.13 | Percent Institutions 56.16 |
Upturn AI SWOT
Aldeyra The
Company Overview
History and Background
Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapies for immune-mediated diseases. Founded in 2004, they initially focused on aldehyde dehydrogenase (ALDH) inhibition, leading to their pipeline of product candidates.
Core Business Areas
- Ophthalmology: Focuses on developing therapies for ocular diseases, including allergic conjunctivitis and dry eye disease.
- Systemic Immunometabolic Diseases: Explores treatments for systemic diseases linked to immune system dysfunction and metabolic processes.
Leadership and Structure
Dr. Todd C. Brady is the President and Chief Executive Officer. The company has a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- Reproxalap: Reproxalap is Aldeyra's lead product candidate, indicated for the treatment of allergic conjunctivitis and dry eye disease. It competes with established treatments like cyclosporine (Restasis) from AbbVie and lifitegrast (Xiidra) from Novartis. Market share data is evolving pending FDA approval and commercial launch. Revenue data is projected. Competitors include AbbVie (Restasis), Novartis (Xiidra) and Sun Pharma (Cequa).
- ADX-2191: ADX-2191 is a intravitreal formulation of methotrexate in development for the treatment of proliferative vitreoretinopathy (PVR). Competitors are off-label methotrexate. The company is also evaluating the unmet needs that ADX-2191 is going to solve.
Market Dynamics
Industry Overview
The ophthalmology market is growing due to aging populations and increased screen time, leading to higher rates of eye diseases. The immunometabolic disease market is also expanding due to increased understanding of these complex conditions.
Positioning
Aldeyra Therapeutics is positioned as an innovator with a novel ALDH inhibitor platform, targeting unmet needs in specific ocular and systemic disease segments.
Total Addressable Market (TAM)
The global dry eye disease market is projected to reach billions of dollars. Aldeyra is positioned to capture a portion of this TAM with Reproxalap, pending FDA approval and commercial success.
Upturn SWOT Analysis
Strengths
- Novel ALDH inhibitor platform
- Lead product candidate (Reproxalap) with promising clinical data
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited commercialization experience
- Dependence on successful clinical trials and FDA approval
- High cash burn rate
- Reliance on a few key product candidates
Opportunities
- FDA approval and commercial launch of Reproxalap
- Expansion of ALDH inhibitor platform to new indications
- Strategic partnerships and collaborations
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Patent challenges
- Generic entry.
Competitors and Market Share
Key Competitors
- ABBV
- NVS
- SNY
Competitive Landscape
Aldeyra's key advantage lies in its novel ALDH inhibitor mechanism, but it faces strong competition from established players with marketed products and larger commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is largely tied to the progression of clinical trials for Reproxalap and other product candidates.
Future Projections: Future projections depend heavily on FDA approval and successful commercialization of Reproxalap.
Recent Initiatives: Recent initiatives include completing clinical trials for Reproxalap, submitting regulatory filings to the FDA, and expanding the pipeline through preclinical research.
Summary
Aldeyra Therapeutics is a clinical-stage biotechnology company with a focus on immune-mediated diseases, particularly in ophthalmology. The company's success hinges on the approval and commercialization of Reproxalap, its lead product candidate. Despite the promise of its novel ALDH inhibitor platform, Aldeyra faces challenges including regulatory hurdles, competition from established pharmaceutical giants, and a high cash burn rate. Potential investors should carefully monitor clinical trial outcomes and regulatory decisions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Aldeyra Therapeutics Investor Relations
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aldeyra The
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2014-05-02 | CEO, President & Director Dr. Todd C. Brady M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.aldeyra.com |
Full time employees 8 | Website https://www.aldeyra.com | ||
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.